Creative Planning Sells 1,395 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)

Creative Planning trimmed its position in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 11.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,540 shares of the medical device company’s stock after selling 1,395 shares during the quarter. Creative Planning’s holdings in Tandem Diabetes Care were worth $447,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 7,052,570 shares of the medical device company’s stock worth $249,732,000 after purchasing an additional 30,664 shares in the last quarter. Fred Alger Management LLC increased its stake in shares of Tandem Diabetes Care by 45.2% in the 2nd quarter. Fred Alger Management LLC now owns 2,174,107 shares of the medical device company’s stock worth $87,595,000 after purchasing an additional 677,036 shares in the last quarter. Bellevue Group AG increased its stake in shares of Tandem Diabetes Care by 2.0% in the 1st quarter. Bellevue Group AG now owns 2,031,888 shares of the medical device company’s stock worth $71,949,000 after purchasing an additional 39,571 shares in the last quarter. Brown Capital Management LLC increased its stake in shares of Tandem Diabetes Care by 29.9% in the 1st quarter. Brown Capital Management LLC now owns 954,567 shares of the medical device company’s stock worth $33,801,000 after purchasing an additional 219,940 shares in the last quarter. Finally, Chicago Capital LLC increased its stake in shares of Tandem Diabetes Care by 22.3% in the 2nd quarter. Chicago Capital LLC now owns 821,062 shares of the medical device company’s stock worth $33,081,000 after purchasing an additional 149,757 shares in the last quarter.

Tandem Diabetes Care Stock Up 3.4 %

Shares of NASDAQ:TNDM opened at $34.24 on Thursday. The company has a current ratio of 3.05, a quick ratio of 2.38 and a debt-to-equity ratio of 1.31. Tandem Diabetes Care, Inc. has a 12 month low of $13.82 and a 12 month high of $53.69. The company has a 50-day moving average price of $39.21 and a 200 day moving average price of $41.88. The company has a market cap of $2.24 billion, a price-to-earnings ratio of -16.38 and a beta of 1.36.

Analysts Set New Price Targets

Several research firms have recently commented on TNDM. Canaccord Genuity Group started coverage on Tandem Diabetes Care in a research note on Thursday, August 8th. They issued a “buy” rating and a $57.00 price objective for the company. The Goldman Sachs Group started coverage on Tandem Diabetes Care in a research note on Friday, October 4th. They issued a “neutral” rating and a $46.00 price target for the company. Barclays increased their price target on Tandem Diabetes Care from $55.00 to $58.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Morgan Stanley reiterated an “equal weight” rating and issued a $45.00 price target on shares of Tandem Diabetes Care in a research note on Monday, September 23rd. Finally, UBS Group upgraded Tandem Diabetes Care to a “hold” rating in a research note on Friday, August 2nd. Five research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of “Moderate Buy” and an average target price of $54.31.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.